Radiation Oncology Journal

  • 제30권2호
  • /
  • Pages.78-87
  • /
  • 2012
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Effect of troglitazone on radiation sensitivity in cervix cancer cells

  • An, Zhengzhe (Department of Radiation Oncology, Chungbuk National University College of Medicine) ;
  • Liu, Xianguang (Department of Radiation Oncology, Chungbuk National University College of Medicine) ;
  • Song, Hye-Jin (Department of Radiation Oncology, Chungbuk National University College of Medicine) ;
  • Choi, Chi-Hwan (Department of Radiation Oncology, Chungbuk National University College of Medicine) ;
  • Kim, Won-Dong (Department of Radiation Oncology, Chungbuk National University College of Medicine) ;
  • Yu, Jae-Ran (Department of Environmental and Tropical Medicine, Konkuk University College of Medicine) ;
  • Park, Woo-Yoon (Department of Radiation Oncology, Chungbuk National University College of Medicine)
  • 투고 : 2012.04.04
  • 심사 : 2012.05.10
  • 발행 : 2012.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Troglitazone (TRO) is a peroxisome proliferator-activated receptor ${\gamma}$ ($PPAR{\gamma}$) agonist. TRO has antiproliferative activity on many kinds of cancer cells via G1 arrest. TRO also increases $Cu^{2+}/Zn^{2+}$-superoxide dismutase (CuZnSOD) and catalase. Cell cycle, and SOD and catalase may affect on radiation sensitivity. We investigated the effect of TRO on radiation sensitivity in cancer cells in vitro. Materials and Methods: Three human cervix cancer cell lines (HeLa, Me180, and SiHa) were used. The protein expressions of SOD and catalase, and catalase activities were measured at 2-10 ${\mu}M$ of TRO for 24 hours. Cell cycle was evaluated with flow cytometry. Reactive oxygen species (ROS) was measured using 2',7'-dichlorofluorescin diacetate. Cell survival by radiation was measured with clonogenic assay. Results: By 5 ${\mu}M$ TRO for 24 hours, the mRNA, protein expression and activity of catalase were increased in all three cell lines. G0-G1 phase cells were increased in HeLa and Me180 by 5 ${\mu}M$ TRO for 24 hours, but those were not increased in SiHa. By pretreatment with 5 ${\mu}M$ TRO radiation sensitivity was increased in HeLa and Me180, but it was decreased in SiHa. In Me180, with 2 ${\mu}M$ TRO which increased catalase but not increased G0-G1 cells, radiosensitization was not observed. ROS produced by radiation was decreased with TRO. Conclusion: TRO increases radiation sensitivity through G0-G1 arrest or decreases radiation sensitivity through catalase-mediated ROS scavenging according to TRO dose or cell types. The change of radiation sensitivity by combined with TRO is not dependent on the PPAR ${\gamma}$ expression level.

키워드

참고문헌

  1. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999;4:611-7. https://doi.org/10.1016/S1097-2765(00)80211-7
  2. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9. https://doi.org/10.2337/diabetes.45.12.1661
  3. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferatoractivated receptors and cancers: complex stories. Nat Rev Cancer 2004;4:61-70. https://doi.org/10.1038/nrc1254
  4. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferatoractivated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 2006;58:1-14. https://doi.org/10.1016/j.critrevonc.2005.08.011
  5. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-52.
  6. Yin F, Wakino S, Liu Z, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 2001;286:916-22. https://doi.org/10.1006/bbrc.2001.5491
  7. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-7. https://doi.org/10.1210/jc.86.5.2170
  8. Park JW, Zarnegar R, Kanauchi H, et al. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 2005;15:222-31. https://doi.org/10.1089/thy.2005.15.222
  9. Han S, Sidell N, Fisher PB, Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 2004;10:1911-9. https://doi.org/10.1158/1078-0432.CCR-03-0985
  10. Li M, Lee TW, Mok TS, Warner TD, Yim AP, Chen GG. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 2005;96:760-74. https://doi.org/10.1002/jcb.20474
  11. Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003;111:1381-8. https://doi.org/10.1172/JCI200316575
  12. Kato M, Kusumi T, Tsuchida S, Tanaka M, Sasaki M, Kudo H. Induction of differentiation and peroxisome proliferatoractivated receptor gamma expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 2004;130:73-9. https://doi.org/10.1007/s00432-003-0510-2
  13. Yu J, Qiao L, Zimmermann L, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006;43:134-43. https://doi.org/10.1002/hep.20994
  14. Koga H, Sakisaka S, Harada M, et al. Involvement of p21(WAF1/ Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001;33:1087-97. https://doi.org/10.1053/jhep.2001.24024
  15. Yoshizawa K, Cioca DP, Kawa S, Tanaka E, Kiyosawa K. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 2002;95:2243-51. https://doi.org/10.1002/cncr.10906
  16. Bae MA, Rhee H, Song BJ. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 2003;139:67-75. https://doi.org/10.1016/S0378-4274(02)00468-X
  17. Wang C, Pattabiraman N, Zhou JN, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 2003;23:6159-73. https://doi.org/10.1128/MCB.23.17.6159-6173.2003
  18. Huang JW, Shiau CW, Yang YT, et al. Peroxisome proliferatoractivated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005;67:1342-8. https://doi.org/10.1124/mol.104.007732
  19. Tafazoli S, Wright JS, O'Brien PJ. Prooxidant and antioxidant activity of vitamin E analogues and troglitazone. Chem Res Toxicol 2005;18:1567-74. https://doi.org/10.1021/tx0500575
  20. Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001;50:3-11. https://doi.org/10.1053/meta.2001.19415
  21. Heo KS, Kim DU, Ryoo S, et al. PPARgamma activation abolishes LDL-induced proliferation of human aortic smooth muscle cells via SOD-mediated down-regulation of superoxide. Biochem Biophys Res Commun 2007;359:1017-23. https://doi.org/10.1016/j.bbrc.2007.06.006
  22. Girnun GD, Domann FE, Moore SA, Robbins ME. Identifi cation of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 2002;16:2793-801. https://doi.org/10.1210/me.2002-0020
  23. Okuno Y, Matsuda M, Kobayashi H, et al. Adipose expression of catalase is regulated via a novel remote PPARgammaresponsive region. Biochem Biophys Res Commun 2008;366: 698-704. https://doi.org/10.1016/j.bbrc.2007.12.001
  24. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazoneinduced liver failure: a case study. Am J Med 2003;114:299- https://doi.org/10.1016/S0002-9343(02)01529-2
  25. Coras R, Holsken A, Seufert S, et al. The peroxisome proliferator- activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther 2007;6:1745-54. https://doi.org/10.1158/1535-7163.MCT-06-0763
  26. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 2006;13:401-13. https://doi.org/10.1677/erc.1.01182
  27. Reddy RC, Srirangam A, Reddy K, et al. Chemotherapeutic drugs induce PPAR-gamma expression and show sequencespecific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia 2008;10:597-603. https://doi.org/10.1593/neo.08134
  28. Welbourne T, Su G, Coates G, Routh R, McCarthy K, Battarbee H. Troglitazone induces a cellular acidosis by inhibiting acid extrusion in cultured rat mesangial cells. Am J Physiol Regul Integr Comp Physiol 2002;282:R1600-7. https://doi.org/10.1152/ajpregu.00506.2001
  29. Xu Y, Lu L, Greyson C, et al. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptorgamma activator in myocardial ischemia and reperfusion in pigs. Diabetes 2003;52:1187-94. https://doi.org/10.2337/diabetes.52.5.1187
  30. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006;118:773-9. https://doi.org/10.1002/ijc.21361
  31. Turturro F, Friday E, Fowler R, Surie D, Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 2004;10:7022-30. https://doi.org/10.1158/1078-0432.CCR-04-0879
  32. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006;6:53. https://doi.org/10.1186/1471-2407-6-53
  33. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54. https://doi.org/10.1016/0003-2697(76)90527-3
  34. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121-6.
  35. Wan XS, Zhou Z, Ware JH, Kennedy AR. Standardization of a fl uorometric assay for measuring oxidative stress in irradiated cells. Radiat Res 2005;163:232-40. https://doi.org/10.1667/RR3299
  36. Yoshioka T, Fujita T, Kanai T, et al. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 1989;32:421-8. https://doi.org/10.1021/jm00122a022
  37. Noguchi N, Sakai H, Kato Y, et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996;123:227-34. https://doi.org/10.1016/0021-9150(96)05811-X
  38. Crawford RS, Mudaliar SR, Henry RR, Chait A. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone. Diabetes 1999;48:783-90. https://doi.org/10.2337/diabetes.48.4.783
  39. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000;36:430-5. https://doi.org/10.1161/01.HYP.36.3.430
  40. Narayanan PK, Hart T, Elcock F, et al. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. Cytometry A 2003;52:28-35.
  41. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 1999;37:91-104. https://doi.org/10.2165/00003088-199937020-00001

피인용 문헌

  1. Troglitazone and tumor inhibition: an evolving concept in the management of systemic malignancies vol.30, pp.4, 2012, https://doi.org/10.3857/roj.2012.30.4.226
  2. A new dawn for the use of thiazolidinediones in cancer therapy vol.23, pp.4, 2012, https://doi.org/10.1517/13543784.2014.884708
  3. Chemotherapy and Chemoprevention by Thiazolidinediones vol.2015, pp.None, 2012, https://doi.org/10.1155/2015/845340
  4. Rosiglitazone enhances radiosensitivity by inhibiting repair of DNA damage in cervical cancer cells vol.56, pp.1, 2012, https://doi.org/10.1007/s00411-016-0679-9
  5. PPARγ Agonists in Combination Cancer Therapies vol.20, pp.3, 2012, https://doi.org/10.2174/1568009619666191209102015